GlassScriptPhysician profile
Joan K Smith
NPI 1407844129
$3,237.26
in general payments reported to CMS, 2019-2025
30 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $890 · 2023: $731 · 2024: $626 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.44 | 2021-2025 | |
| Novo Nordisk INC | $451.03 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $315.64 | 2021-2025 | |
| Astellas Pharma US INC | $249.60 | 2021-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $217.04 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $211.45 | 2022-2025 | |
| Mylan Specialty L.P. | $147.05 | 2023-2024 | Yupelri |
| Amgen INC. | $129.94 | 2021-2023 | Evenity, Prolia |
| Pfizer INC. | $119.69 | 2021-2025 | |
| Glaxosmithkline, LLC. | $99.49 | 2021-2024 | Trelegy Ellipta, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $72.73 | 2021-2025 | Camzyos |
| Inspire Medical Systems, INC. | $69.70 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $67.56 | 2021-2023 | Dificid, Zerbaxa |
| Lundbeck LLC | $67.01 | 2024-2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $64.10 | 2023-2025 | Uptravi, Opsumit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $60.61 | 2022-2023 | Prolastin-C Liquid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.60 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.22 | 2021-2025 | |
| Boston Scientific Corporation | $35.66 | 2023 | Watchman Access System |
| Neurocrine Biosciences, INC. | $32.33 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.21 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $25.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.27 | 2021-2022 | |
| Baxter Healthcare | $23.64 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Radius Health, INC. | $20.59 | 2021 | |
| Insulet Corporation | $19.61 | 2025 | Omnipod |
| Scpharmaceuticals INC. | $17.53 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.43 | 2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $14.18 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.